These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3279969)

  • 1. Decrease in LDL and increase in HDL concentrations in type II hyperlipoproteinaemic patients on low-dose combination therapy of cholestyramine and Complamin.
    Fears R; Ferres H; Haacke H; Mäder C; Parwaresch MR
    Atherosclerosis; 1988 Feb; 69(2-3):97-101. PubMed ID: 3279969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.
    Jones DB; Simpson HC; Slaughter P; Lousley S; Carter RD; Cobbe SM; Mann JI
    Atherosclerosis; 1984 Oct; 53(1):1-7. PubMed ID: 6388586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
    Series JJ; Gaw A; Kilday C; Bedford DK; Lorimer AR; Packard CJ; Shepherd J
    Br J Clin Pharmacol; 1990 Jul; 30(1):49-54. PubMed ID: 2390432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combination cholestyramine-neomycin treatment on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
    Hoeg JM; Maher MB; Bailey KR; Zech LA; Gregg RE; Sprecher DL; Brewer HB
    Am J Cardiol; 1985 May; 55(11):1282-6. PubMed ID: 3887883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholestyramine in type IIa hyperlipoproteinemia. Is low-dose treatment feasible?
    Angelin B; Einarsson K
    Atherosclerosis; 1981; 38(1-2):33-8. PubMed ID: 7470203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum lipoproteins during childhood: normal concentrations and primary hyperlipoproteinemias.
    Widhalm K
    Bibl Nutr Dieta; 1982; (31):140-3. PubMed ID: 6985556
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated charcoal in the treatment of hypercholesterolaemia: dose-response relationships and comparison with cholestyramine.
    Neuvonen PJ; Kuusisto P; Vapaatalo H; Manninen V
    Eur J Clin Pharmacol; 1989; 37(3):225-30. PubMed ID: 2612535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholestyramine plus pectin in treatment of patients with familial hypercholesterolemia.
    Schwandt P; Richter WO; Weisweiler P; Neureuther G
    Atherosclerosis; 1982 Sep; 44(3):379-83. PubMed ID: 7150399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Cheung J; Crook MA
    QJM; 1997 Oct; 90(10):631-4. PubMed ID: 9415344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
    Leitersdorf E; Muratti EN; Eliav O; Meiner V; Eisenberg S; Dann EJ; Sehayek E; Peters TK; Stein Y
    Am J Med; 1994 May; 96(5):401-7. PubMed ID: 8192170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.
    Simons LA; Hickie JB; Balasubramaniam S
    Atherosclerosis; 1985 Jan; 54(1):75-88. PubMed ID: 3888229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
    Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E
    Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].
    Haacke H; Parwaresch MR; Mäder C
    Med Klin; 1977 Jul; 72(27):1183-7. PubMed ID: 196168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia.
    Series JJ; Caslake MJ; Kilday C; Cruickshank A; Demant T; Lorimer AR; Packard CJ; Shepherd J
    Metabolism; 1989 Feb; 38(2):153-8. PubMed ID: 2643751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with simvastatin compared with cholestyramine.
    Erkelens DW; Baggen MG; Van Doormaal JJ; Kettner M; Koningsberger JC; Mol MJ
    Drugs; 1988; 36 Suppl 3():87-92. PubMed ID: 3254824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K; Djaja S; Richter E
    Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.